Comprehensive management guideline for breast cancer follow-up and healthcare (2022 edition) / 中华肿瘤杂志

ABSTRACT

In recent years, with the emphasis on breast cancer screening and the improvement of standardized diagnosis and treatment, cure rate and survival time of breast cancer patients have been significantly improved in China. Accompanied by prolonged follow-up period, patients are facing increasing cancer and other related health issues, which calls for a more accurate and long-term follow-up plan and focus on broader health risks. Health issues on cardiovascular system, bone density, blood lipid and psychology caused by anti-cancer treatment, senescence or changes in hormone levels have become new challenges in the management of patients with breast cancer, not only affecting the life quality, but also impacting disease recurrence and death. Therefore, in addition to standardized treatment, scientific and standardized follow-up, comprehensive management of patients' concomitant diseases, interdisciplinary cooperation and holistic rehabilitation are also vital links to treatment. This could improve the therapeutic efficacy of anti-cancer treatment and the quality of life of patients. Based on the current landscape of treatment and follow-up of breast cancer patients in China, the experts committee updated the "Comprehensive Management Guideline for Breast Cancer Follow-up and Concomitant Diseases (2019 edition)" and revised it as "Guidelines for breast cancer follow-up and health management in China (2022 edition)" according to the latest literature and guidelines and medical advice from interdisciplinary experts. This new guideline is composed of four parts path diagram, follow-up management, comprehensive healthcare management, and patient reported outcome. It aims to standardize the long-term follow-up of breast cancer patients, guide clinicians to actively provide comprehensive interdisciplinary healthcare management, and further improve the prognosis and life quality of breast cancer patients in China.